HomeHeadlinesLilly's (LLY) oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsJUNE 8, 2026 AT 06:31 PMLilly's (LLY) oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsByNewsquawk StaffImportanceLevel 1#ELI LILLY & CO#LLY.US#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIESExternal
JUNE 8, 2026 AT 06:31 PMLilly's (LLY) oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trialsByNewsquawk StaffImportanceLevel 1#ELI LILLY & CO#LLY.US#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIESExternal
